Outcomes, survival, and HRQOL in trials of new drugs (and what they mean in practice)

A new paper in the journal Quality of Life Research has raised the question of whether it is possible to use available quality of life data from Phase III trials of new drugs in the treatment of advanced prostate cancer to make rational decisions about the use of those drugs in clinical practice. … READ MORE …

Patient-reported outcomes and quality of life in the ProtecT trial

We have already commented on the oncologic outcomes of patients enrolled in the ProtecT trial and published in today’s issue of the New England Journal of Medicine. In this commentary we shall comment on the separate paper that addresses patient-reported outcomes from that trial. … READ MORE …